(46-二氯吡啶-2-基)甲醇 | 1244949-68-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: (46-二氯吡啶-2-基)甲醇
• 英文名称: (4,6-Dichloropyrimidin-2-yl)methanol
• CAS: 1244949-68-5
• 化学式: C₅H₄Cl₂N₂O
• mdl: MFCD11617830
• 分子量: 179.0
• InChiKey: NYUNBUWGWXSQGF-UHFFFAOYSA-N

物化性质

• 沸点：
  274.1±30.0 °C(Predicted)
• 密度：
  1.575±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20190308950A1

  公开（公告）日：2019-10-10

  Substituted pyrimidine and pyridines as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  用嘧啶和吡啶替代作为NR2B受体配体。这些化合物可用于NR2B受体调节以及用于治疗由NR2B受体活性介导的疾病状态、紊乱和病况的药物组合物和方法。
• [EN] HETEROARYL INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] INHIBITEURS HÉTÉROARYLE DE LA KALLICRÉINE PLASMATIQUE
  申请人：SHIRE HUMAN GENETIC THERAPIES

  公开号：WO2022197758A1

  公开（公告）日：2022-09-22

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了一种化合物及其组合物，可用作血浆卡利肌酶的抑制剂，并表现出相同的理想特性。
• Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11008302B2

  公开（公告）日：2021-05-18

  Substituted pyrimidine and pyridines as NR2B receptor ligands, for example Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  作为 NR2B 受体配体的取代嘧啶和吡啶，例如 这类化合物可用于 NR2B 受体调节以及治疗由 NR2B 受体活性介导的疾病状态、失调和病症的药物组合物和方法中。
• [EN] SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] PYRIDINE ET PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019193516A2

  公开（公告）日：2019-10-10

  Substituted pyrimidine and pyridines as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.